Breaking News, Collaborations & Alliances

BridgeBio and Kyowa Kirin Partner to Advance Development of Infigratinib

The collaboration aims to ensure the development of infigratinib for children living with achondroplasia, and eventually for other skeletal dysplasias in Japan.

Author Image

By: Charlie Sternberg

Associate Editor

BridgeBio Pharma Inc. and Kyowa Kirin Co., Ltd have announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.   In exchange, BridgeBio will receive an upfront payment of $100 million as well as royalties up to the high-twenties percent on sales of infigratinib in Japan, with the potential for additional milestone-based p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters